Assignee
SHANGHAI CELGEN BIO PHARMACEUTICAL CO LTD
CN·0 granted patents·6 pending applications·0 citations·filing 2022–2023
Top patents by PatentIndex Score
6 records- 0176US2025333507A1Fusion protein of anti-tigit antibody and il2 or variant thereof, and application thereofSHANGHAI CELGEN BIO PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 0271US2024400680A1Fusion protein of anti-tigit antibody and il2 or variant thereof and application thereofSHANGHAI CELGEN BIO PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 0371US2024417462A1Monoclonal antibody targeting tigitSHANGHAI CELGEN BIO PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 0461US2025136654A1Anti-her-2 antibody-granulocyte regulatory factor fusion protein, preparation method therefor and application thereofSHANGHAI CELGEN BIO PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 0560US2024150432A1Fusion protein of tnfr2 and april baff receptorSHANGHAI CELGEN BIO PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 0659US2024392024A1Anti-tnfr2 monoclonal antibody and application thereofSHANGHAI CELGEN BIO PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when SHANGHAI CELGEN BIO PHARMACEUTICAL CO LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →